„Ecstasy” (3,4-Methylendioxymethamphetamin, MDMA) ist eine in der Technoszene verbreitete Droge. Die vorliegende Übersicht konzentriert sich nach einer Zusammenfassung der Pharmakologie und Toxikologie von MDMA auf das Management einer Intoxikation mit MDMA oder andere Substanzen, die unter dem Namen Ecstasy verkauft werden.
Abstract
„Ecstasy” (3,4-methylene dioxymethamphetamine = MDMA) is a drug widely used among „techno” fans. The following survey after summarising the pharmacology and toxicology of MDMA, focusses on the management of an intoxication with MDMA or with other substances marketed under the „Exstasy” label.
Schlüsselwörter
„Ecstasy” - MDMA - andere „Ecstasy”-Substanzen - Intoxikation - Management
1 Baggott M, Stuart R, Jerome L. Medical emergencies and adverse events in ecstasy users. In: Baggott M, Jerome L, Stuart R (eds) 3,4-Methylenedioxymethamphetamine (MDMA): A review of the English-language scientific and medical literature. Multidisciplinary Association for Psychodelic Studies http://www.maps.org
2
Balmelli C, Kupferschmidt H, Rentsch K, Schneemann M.
Tödliches Hirnödem nach Einnahme von Ecstasy und Benzylpiperazin.
Dtsch Med Wochenschr.
2001;
126
809-811
5
Cole J C, Bailey M, Sumnall H R, Wagstaff G F, King L A.
The content of ecstasy tablets: implications for the study of their long-term effects.
Addiction.
2002;
97
1531-1536
7
Dughiero G, Schifano F, Forza G.
Personality dimensions and psychopathological profiles of Ecstasy users.
Human Psychopharmacol Clin Exp.
2001;
16
635-639
8 Gamma A, Liechti M E. The psychophysiology of substance-related disorders. In: D'haenen H, Boer JA Den, Willner P (eds) Biological Psychiatry. London; Wiley 2002: 467-493
9
Giroud C, Augsburger M, Sadeghipour F, Varesio E, Veuthey J-L, Rivier L.
Ecstasy - la situation en Suisse romande. Composition des saisies, analyse des échantillons biologiques et brève revue de son action pharmacologique et de sa toxicité.
Schweiz Rundsch Med Prax.
1997;
86
510-523
11
Gouzoulis-Mayfrank E, Daumann J, Sass H.
Neurotoxische Langzeitschäden bei Ecstasy(MDMA)-Konsumenten: Überblick über den aktuellen Wissensstand.
Nervenarzt.
2002;
73
405-421
12
Gouzoulis-Mayfrank E, Hermle L, Kovar K-A, Sass H.
Die entaktogene „Ecstasy” (MDMA), „Eve” (MDE) und andere ringsubstituierte Methamphetaminderivate.
Nervenarzt.
1996;
67
369-380
13
Gouzoulis-Mayfrank E, Thelen B, Habermeyer E. et al .
Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers.
Psychopharmacology.
1999;
142
41-50
14
Harris D S, Baggott M, Mendelson J H, Mendelson J E, Jones R T.
Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans.
Psychopharmacology.
2002;
162
396-405
15
Hartung T K, Schofield E, Short A I, Parr M JA, Henry J A.
Hyponatriaemic states following 3,4-methylenedioxymethamphetamine (MDMA, „ecstasy”) ingestion.
Q J Med.
2002;
95
431-437
20 Henry J A, Rella J G. Medical risks associated with MDMA use. In: Holland J (ed) Ecstasy: the complete guide - A comprehensive look at the risks and benefits of MDMA. Rochester, Vermont; Park Street Press 2001: 71-86
21
Hernández Lopez C, Farré M, Roset P N. et al .
3,4-Methylenedioxymethamphetamine (Ecstasy) and alcohol interactions in humans: psychomotor performance, subjective effects, and pharmacokinetics.
J Pharmacol Exp Ther.
2002;
300
236-244
22 Johnston L D, O'Malley P M, Bachman J G. Monitoring the Future national survey results on drug use, 1975 - 2001. Volume I: Secondary school students. Bethesda, MD; National Institute on Drug Abuse 2002 NIH Publication No. 02-5106
23 Kupferschmidt H, Wyss P A, Fattinger K, Meier-Abt P J. Medizinische Probleme beim Konsum illegaler Drogen. In: Grundlagen der Arzneimitteltherapie. Basel; Documed 2001
25
Lester S J, Baggott M, Welm S. et al .
Cardiovascular effects of 3,4-methylenedioxymethamphetamine. A double-blind placebo-controlled trial.
Ann Int Med.
2000;
133
969-973
27
Liechti M E, Baumann C, Gamma A, Vollenweider F X.
Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, „Ecstasy”) are attenuated by the serotonin uptake inhibitor citalopram.
Neuropsychopharmacology.
2000;
22
513-521
30
Liechti M E, Saur M, Gamma A, Hell D, Vollenweider F X.
Psychological and physiological effects of MDMA („Ecstasy”) after pretreatment with the 5-HT2 antagonist ketanserin in healthy humans.
Neuropsychopharmacology.
2000;
23
396-404
31
Liechti M E, Vollenweider F X.
Acute psychological and physiological effects of MDMA („Ecstasy”) after haloperidol pretreatment in healthy humans.
Eur Neuropsychopharmacol.
2000;
10
289-295
32
Liechti M E, Vollenweider F X.
The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine („Ecstasy”) in healthy volunteers.
J Psychopharmacol.
2000;
14
269-274
33
Liechti M E, Vollenweider F X.
Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies.
Hum Psychopharmacol Clin Exp.
2001;
16
589-598
35
McCann U D, Szabo Z, Scheffel U, Dannals R F, Ficaurte G A.
Positron emission tomographic evidence of toxic effect of MDMA („Ecstasy”) on brain serotonin neurons in human beings.
Lancet.
1998;
352
1433-1437
39
Nichols D E.
Differences between the mechanism of action of MDMA, MBDB, and the classical hallucinogens. Identification of a new therapeutic class: Entactogens.
J Psychoactive Drugs.
1986;
18
305-313
40
Reneman L, Booij J, Reitsma J B. et al .
Effects of dose, sex, and long-term abstention from use of toxic effects of MDMA (ecstasy) on brain serotonin neurons.
Lancet.
2001;
358
1864-1869
41
Ricaurte G A, Yuan J, Hatzidimitriou G, Cord B J, McCann U D.
Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA („Ecstasy”).
Science.
2002;
297
2260-2263
42 SFA/ISPA .Ecstasy in der Schweiz, die erste repräsentative Studie zur Modedroge. Lausanne; SFA (Schweizerische Fachstelle für Alkohol- und andere Drogenprobleme) 1996
43
Soar K, Turner J JD, Parrott A C.
Psychiatric disorders in Ecstasy (MDMA) users: a literature review focusing on personal predisposition and drug history.
Hum Psychopharmacol Clin Exp.
2001;
16
641-645
45
Verheyden S L, Hadfield J, Calin T, Curran H V.
Subacute effects of MDMA (plusmn 3,4-methylenedioxymethamphetamine, „ecstasy”) on mood: evidence of gender differences.
Psychopharmacology.
2002;
161
23-31
46
Sydow K von, Lieb R, Pfister H, Höfler M, Wittchen H-U.
Use, abuse and dependence of ecstasy and related drugs in adolescents and young adults - a transient phenomenon? Results of a longitudinal community study.
Drug Alcohol Depend.
2002;
66
147-159
47
Williams H, Dratcu L, Taylor R, Roberts M, Oyefeso A.
„Saturday night fever”: ecstasy related problems in a London accident and emergency department.
J Accid Emerg Med.
1998;
15
322-367
